Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Brings Substantial Experience in Product Development of Multiple Catheter-Based Technologies for Use in the Vascular Anatomy

Hansen Medical , Inc. (HNSN 1.56, -0.03, -1.89%) , a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, announced that engineering executive Jean Chang has been named Vice President, Engineering, effective immediately. Chang will report directly to President and CEO Bruce Barclay.

Chang, 50, spent the past seven years as Vice President, Engineering and Operations at CardioMind Inc., a developer of guidewire based stent systems for interventional cardiology and neuroradiology that was sold to Biosensors earlier this year. Along with responsibilities for R&D and operations, Chang was also involved in regulatory and clinical affair activities for CardioMind.

"Jean has a broad background in research and development of catheter-based products, including a strong clinical understanding of how these devices are used in the hands of physicians, which translates well for our needs here at Hansen Medical ," Barclay said. "Her technical expertise lends itself to product development from inception through pre-clinical testing and regulatory approval, which will help us as we work closely with European and U.S. regulators on our flexible robotic systems, both for electrophysiology and vascular applications. Perhaps most importantly, multiple technology programs that she has managed have resulted in commercially successful products and are now used widely in both coronary and peripheral clinical applications. We look forward to Jean joining our team."

" Hansen Medical 's flexible robotic platforms offer tremendous potential in the vascular space by improving procedural times and ultimately clinical outcomes in difficult diseased anatomies. I am excited to join Hansen and work with the talented technical teams towards commercialization and clinical adoption of Hansen's innovative robotic catheter systems," said Chang.

Prior to her work at CardioMind, Chang spent six years in various capacities at EMBOL-X, a company that developed various embolic protection devices for cardiac surgery before it was sold to Edwards Lifesciences in 2003. She was Chief Operating Officer from November 2000 until the sale of the company. Chang has also worked in various management positions at Cordis and Advanced Cardiovascular Systems/Guidant. She has bachelor's degrees in Materials Science and Engineering, and Life Sciences from MIT. She also holds a Master of Science degree in Bioengineering from UC San Francisco.

Source: Hansen Medical , Inc.